Revance Therapeutics Inc (RVNC) concluded trading on Thursday at a closing price of $3.63, with 8.17 million shares of worth about $29.66 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -1.89% during that period and on January 30, 2025 the price saw a loss of about -0.27%. Currently the company’s common shares owned by public are about 104.90M shares, out of which, 95.25M shares are available for trading.
Stock saw a price change of -1.09% in past 5 days and over the past one month there was a price change of 18.63%. Year-to-date (YTD), RVNC shares are showing a performance of 19.41% which decreased to -39.90% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.30 but also hit the highest price of $7.56 during that period. The average intraday trading volume for Revance Therapeutics Inc shares is 2.97 million. The stock is currently trading 5.65% above its 20-day simple moving average (SMA20), while that difference is up 5.03% for SMA50 and it goes to -12.83% lower than SMA200.
Revance Therapeutics Inc (NASDAQ: RVNC) currently have 104.90M outstanding shares and institutions hold larger chunk of about 85.71% of that.
The stock has a current market capitalization of $378.94M and its 3Y-monthly beta is at 0.90. It has posted earnings per share of -$1.92 in the same period. It has Quick Ratio of 3.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RVNC, volatility over the week remained 0.88% while standing at 1.94% over the month.
Stock’s fiscal year EPS is expected to rise by 42.23% while it is estimated to increase by 38.16% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on January 29, 2024 offering a Neutral rating for the stock and assigned a target price range of between $16 and $9 to it. Coverage by Goldman stated Revance Therapeutics Inc (RVNC) stock as a Neutral in their note to investors on January 09, 2024, suggesting a price target of $8 for the stock. On August 16, 2023, Exane BNP Paribas Upgrade their recommendations, while on October 11, 2022, Morgan Stanley Initiated their ratings for the stock with a price target of $27. Stock get a Buy rating from Goldman on September 22, 2022.
